Want to see VASO full AI Analyst Report?
Top Page
Vaso
(OTC:VASO)
Select Model
Select Model
Rating:63Neutral
Price Target:
$0.31
▲(64.21% Upside)
Action:Reiterated
Date:08/20/26
Overall score reflects a solid financial foundation (low leverage and supportive cash generation) but tempered by weakening TTM revenue and materially compressed profitability versus 2022–2023. Technically, the stock is in an uptrend but appears overbought, while valuation looks only average given a moderate P/E and no dividend.
Positive Factors
Low Leverage
A conservatively positioned balance sheet reduces refinancing risk and preserves financial flexibility. Low leverage should help Vaso absorb operating volatility and maintain strategic options over the next several quarters.
Negative Factors
Revenue Contraction
Recent revenue contraction signals weaker demand, customer activity, or business scale than in the prior period. Without a return to sustainable growth, lower revenue can limit operating leverage and make margin recovery more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A conservatively positioned balance sheet reduces refinancing risk and preserves financial flexibility. Low leverage should help Vaso absorb operating volatility and maintain strategic options over the next several quarters.
Read all positive factors
Vaso (VASO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.81M
Dividend YieldN/A
Average Volume (3M)98.46K
Price to Earnings (P/E)17.8
Beta (1Y)0.70
Revenue Growth-8.03%
EPS GrowthN/A
CountryUS
Employees282
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.02
Shares Outstanding176,018,040
10 Day Avg. Volume66,687
30 Day Avg. Volume98,461
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.04
Price to Sales (P/S)0.35
P/FCF Ratio3.68
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaso Business Overview & Revenue Model
Company Description
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisi...
Vaso Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.22M | 89.10M | 86.77M | 81.02M | 80.02M | 75.58M |
| Gross Profit | 51.98M | 54.67M | 52.05M | 50.59M | 48.48M | 43.13M |
| EBITDA | 424.00K | -423.00K | 2.10M | 5.95M | 8.38M | 6.66M |
| Net Income | 2.79M | 1.57M | 951.00K | 4.80M | 11.87M | 6.10M |
Balance Sheet | ||||||
| Total Assets | 85.91M | 88.35M | 82.94M | 75.76M | 72.66M | 52.36M |
| Cash, Cash Equivalents and Short-Term Investments | 38.29M | 35.05M | 26.27M | 25.32M | 20.32M | 6.65M |
| Total Debt | 1.79M | 1.81M | 2.38M | 2.06M | 1.80M | 1.39M |
| Total Liabilities | 56.70M | 58.92M | 55.24M | 48.91M | 49.78M | 41.05M |
| Stockholders Equity | 29.21M | 29.43M | 27.70M | 26.84M | 22.88M | 11.31M |
Cash Flow | ||||||
| Free Cash Flow | 6.90M | 8.35M | 1.83M | 4.57M | 13.85M | 7.40M |
| Operating Cash Flow | 7.86M | 9.27M | 3.28M | 5.30M | 14.42M | 7.82M |
| Investing Cash Flow | -821.00K | -725.00K | 11.73M | -5.66M | -8.42M | -260.00K |
| Financing Cash Flow | -834.00K | 248.00K | -89.00K | -134.00K | -230.00K | -8.33M |
Vaso Risk Analysis
Vaso disclosed 32 risk factors in its most recent earnings report. Vaso reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vaso Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $49.81M | 17.75 | 9.91% | ― | -8.03% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $27.13M | -0.93 | -686.78% | ― | ― | 26.80% | |
44 Neutral | $13.00M | -0.01 | -68.42% | ― | 116.40% | 99.31% | |
40 Underperform | $1.30M | -0.05 | -9999.00% | ― | -9.31% | 89.43% |
* Healthcare Sector Average
VASO
Vaso
0.29
0.17
139.17%
HCTI
Healthcare Triangle
0.84
-141.36
-99.41%
BEAT
HeartBeam
0.49
-0.79
-61.81%
VSEE
VSee Health
0.02
-0.75
-97.14%
BFRG
BullFrog AI Holdings, Inc.
0.57
-0.67
-54.07%
MGRX
Mangoceuticals, Inc.
0.40
-1.85
-82.22%
Vaso Corporate Events
Business Operations and StrategyM&A Transactions
Vaso Completes Sale of NetWolves Network Services
Neutral
Jul 31, 2026
On July 31, 2026, Vaso Corporation and its subsidiary VasoTechnology, Inc. completed the sale of all issued and outstanding membership interests in NetWolves Network Services LLC to COEO Solutions, LLC under an Equity Purchase Agreement. The cash ...
Executive/Board Changes
Vaso Adds Financial Expert Shaun McMeans to Board
Positive
Jul 23, 2026
On July 23, 2026, Vaso Corporation appointed 64-year-old finance executive Shaun McMeans as a Class III director and member of its audit committee, effective immediately. The move adds a designated financial expert to the board, reinforcing govern...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.